Hemostemix (CVE:HEM) Stock Price Up 71.4% – Should You Buy?

Hemostemix Inc. (CVE:HEMGet Free Report) shares rose 71.4% on Tuesday . The stock traded as high as C$0.12 and last traded at C$0.12. Approximately 592,088 shares changed hands during trading, an increase of 517% from the average daily volume of 95,938 shares. The stock had previously closed at C$0.07.

Hemostemix Stock Up 71.4 %

The stock’s fifty day simple moving average is C$0.08 and its 200-day simple moving average is C$0.07. The company has a market capitalization of C$10.45 million, a PE ratio of -6.00 and a beta of 0.20.

Hemostemix Company Profile

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Featured Articles

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.